CV Therapeutics’ Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c And Other Markers Of Diabetes In MERLIN TIMI-36
Nov 6th 2007Drug InformationClinical Trials
CV Therapeutics, Inc. (Nasdaq: CVTX) announced that data from a prospectively identified analysis of 2,220 diabetic patients from the MERLIN TIMI-36 study showed that Ranexa(R) (ranolazine extended-release tablets) significantly reduced hemoglobin A1c (HbA1c), increased the number of patients achieving the clinical HbA1c treatment target of 7.0 percent or less and reduced the incidence of newly increased HbA1c in patients without diabetes at baseline. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
